Cargando…

'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease.

The only hope for effective treatment of hepatocellular carcinoma (HCC or 'hepatoma') lies in early diagnosis. Measurement of the serum alphafetoprotein (AFP) level is potentially a useful screening test. When grossly raised, it is almost diagnostic of HCC. However, modestly elevated level...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, P. J., Leung, N., Cheng, P., Welby, C., Leung, W. T., Lau, W. Y., Yu, S., Ho, S.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1997
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063272/
https://www.ncbi.nlm.nih.gov/pubmed/9010032
_version_ 1782137302181478400
author Johnson, P. J.
Leung, N.
Cheng, P.
Welby, C.
Leung, W. T.
Lau, W. Y.
Yu, S.
Ho, S.
author_facet Johnson, P. J.
Leung, N.
Cheng, P.
Welby, C.
Leung, W. T.
Lau, W. Y.
Yu, S.
Ho, S.
author_sort Johnson, P. J.
collection PubMed
description The only hope for effective treatment of hepatocellular carcinoma (HCC or 'hepatoma') lies in early diagnosis. Measurement of the serum alphafetoprotein (AFP) level is potentially a useful screening test. When grossly raised, it is almost diagnostic of HCC. However, modestly elevated levels may also arise in patients with benign chronic liver disease, and this markedly decreases the test's specificity and hence its clinical value. In 582 consecutive attendees at an outpatient clinic for people with chronic liver disease, a single blood sample was taken for analysis of 'total' AFP and the 'hepatoma-specific' AFP isoform. Using ultrasonography as the primary screening method, patients with AFP levels > or = 50 ng ml-1 were followed up throughout the study or until HCC was diagnosed on the basis of conventionally defined criteria. On entry into the study, 53 patients had an AFP concentration > = or 50 ng ml-1 and the 'hepatoma-specific' AFP isoform was detected in 26 of these. During an 18-month follow-up period, a diagnosis of HCC was established by conventional methods in 19 (17 'definite' and two 'probable') of these 26 patients. In only two cases was there ultrasound evidence of tumour development at the time AFP was first found to be elevated; in the remainder a diagnosis of HCC, based on ultrasound screening, was established at a median time of 3.6 months (range 1-18 months) after entry into the study. Among those 27 without the 'hepatoma-specific' isoform, one developed a 'definite' HCC and two developed 'probable' tumours. With the application of 'hepatoma-specific' AFP, the positive predictive value of the test was 73.1%, compared with only 41.5% using the conventional 'total' AFP test. Application of this test for the 'hepatoma-specific' AFP markedly increases the positive predictive value of AFP and, in some cases, permits the presence of tumour to be inferred before it could be detected by routine ultrasound examination. IMAGES:
format Text
id pubmed-2063272
institution National Center for Biotechnology Information
language English
publishDate 1997
publisher Nature Publishing Group|1
record_format MEDLINE/PubMed
spelling pubmed-20632722009-09-10 'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease. Johnson, P. J. Leung, N. Cheng, P. Welby, C. Leung, W. T. Lau, W. Y. Yu, S. Ho, S. Br J Cancer Research Article The only hope for effective treatment of hepatocellular carcinoma (HCC or 'hepatoma') lies in early diagnosis. Measurement of the serum alphafetoprotein (AFP) level is potentially a useful screening test. When grossly raised, it is almost diagnostic of HCC. However, modestly elevated levels may also arise in patients with benign chronic liver disease, and this markedly decreases the test's specificity and hence its clinical value. In 582 consecutive attendees at an outpatient clinic for people with chronic liver disease, a single blood sample was taken for analysis of 'total' AFP and the 'hepatoma-specific' AFP isoform. Using ultrasonography as the primary screening method, patients with AFP levels > or = 50 ng ml-1 were followed up throughout the study or until HCC was diagnosed on the basis of conventionally defined criteria. On entry into the study, 53 patients had an AFP concentration > = or 50 ng ml-1 and the 'hepatoma-specific' AFP isoform was detected in 26 of these. During an 18-month follow-up period, a diagnosis of HCC was established by conventional methods in 19 (17 'definite' and two 'probable') of these 26 patients. In only two cases was there ultrasound evidence of tumour development at the time AFP was first found to be elevated; in the remainder a diagnosis of HCC, based on ultrasound screening, was established at a median time of 3.6 months (range 1-18 months) after entry into the study. Among those 27 without the 'hepatoma-specific' isoform, one developed a 'definite' HCC and two developed 'probable' tumours. With the application of 'hepatoma-specific' AFP, the positive predictive value of the test was 73.1%, compared with only 41.5% using the conventional 'total' AFP test. Application of this test for the 'hepatoma-specific' AFP markedly increases the positive predictive value of AFP and, in some cases, permits the presence of tumour to be inferred before it could be detected by routine ultrasound examination. IMAGES: Nature Publishing Group|1 1997 /pmc/articles/PMC2063272/ /pubmed/9010032 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Johnson, P. J.
Leung, N.
Cheng, P.
Welby, C.
Leung, W. T.
Lau, W. Y.
Yu, S.
Ho, S.
'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease.
title 'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease.
title_full 'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease.
title_fullStr 'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease.
title_full_unstemmed 'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease.
title_short 'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease.
title_sort 'hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063272/
https://www.ncbi.nlm.nih.gov/pubmed/9010032
work_keys_str_mv AT johnsonpj hepatomaspecificalphafetoproteinmaypermitpreclinicaldiagnosisofmalignantchangeinpatientswithchronicliverdisease
AT leungn hepatomaspecificalphafetoproteinmaypermitpreclinicaldiagnosisofmalignantchangeinpatientswithchronicliverdisease
AT chengp hepatomaspecificalphafetoproteinmaypermitpreclinicaldiagnosisofmalignantchangeinpatientswithchronicliverdisease
AT welbyc hepatomaspecificalphafetoproteinmaypermitpreclinicaldiagnosisofmalignantchangeinpatientswithchronicliverdisease
AT leungwt hepatomaspecificalphafetoproteinmaypermitpreclinicaldiagnosisofmalignantchangeinpatientswithchronicliverdisease
AT lauwy hepatomaspecificalphafetoproteinmaypermitpreclinicaldiagnosisofmalignantchangeinpatientswithchronicliverdisease
AT yus hepatomaspecificalphafetoproteinmaypermitpreclinicaldiagnosisofmalignantchangeinpatientswithchronicliverdisease
AT hos hepatomaspecificalphafetoproteinmaypermitpreclinicaldiagnosisofmalignantchangeinpatientswithchronicliverdisease